Other large studies have also confirmed that the presence of MRG and NPM1 mutations, in the absence of FLT3-ITD, does not alter the favorable prognoses and treatment outcomes of patients with NPM1-mutated AML [97,98]. The gene discussed is NPM1; the disease is acute myeloid leukemia.